Clinical data | |
---|---|
Pronunciation | /ˈmɛznə/ |
AHFS/Drugs.com | Monograph |
Pregnancy category |
|
Routes of administration | By mouth, intravenous |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | 45–79% (by mouth) |
Metabolism | Oxidised in circulation |
Elimination half-life | 0.36–8.3 hours |
Excretion | kidney |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.039.336 |
Chemical and physical data | |
Formula | C2H5NaO3S2 |
Molar mass | 164.17 g·mol−1 |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
Mesna, sold under the brand name Mesnex among others, is a medication used in those taking cyclophosphamide or ifosfamide to decrease the risk of bleeding from the bladder.[1] It is used either by mouth or injection into a vein.[1]
Common side effects include headache, vomiting, sleepiness, loss of appetite, cough, rash, and joint pain.[1] Serious side effects include allergic reactions.[1] Use during pregnancy appears to be safe for the baby but this use has not been well studied.[2] Mesna is an organosulfur compound.[3] It works by altering the breakdown products of cyclophosphamide and ifosfamide found in the urine making them less toxic.[1]
Mesna was approved for medical use in the United States in 1988.[1] It is on the World Health Organization's List of Essential Medicines.[4]